EP2878296A1 — Pharmaceutical composition comprising lacosamide and levetiracetam
Assigned to UCB Pharma GmbH · Expires 2015-06-03 · 11y expired
What this patent protects
The present application relates to a fixed dose combination comprising lacosamide and levetiracetam, as well as to dosage regimes including such fixed dose combinations. The fixed dose combinations are suitable for the oral or parenteral treatment of various diseases, including e…
USPTO Abstract
The present application relates to a fixed dose combination comprising lacosamide and levetiracetam, as well as to dosage regimes including such fixed dose combinations. The fixed dose combinations are suitable for the oral or parenteral treatment of various diseases, including epilepsy and/or epileptic seizures.
Drugs covered by this patent
- Keppra (levetiracetam) · Generic (originally UCB Pharma)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.